Alkermes plc (Nasdaq: ALKS) announced preliminary topline results from FORWARD-3 and FORWARD-4, the first two of three phase 3 efficacy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

UBS Remains Sidelined on Alkermes plc (ALKS) Following Failed ALKS 5461 StudiesJanuary 22, 2016 9:40 AM Morgan Stanley Downgrades Alkermes (ALKS) to UnderweightJanuary 21, 2016 12:52 PM Alkermes (ALKS) PT Cut to $58 at Leerink Partners; Maintains 'Outperform'January 21, 2016 10:07 AM Cowen Downgrades Alkermes (ALKS) to Market PerformJanuary 21, 2016 9:51 AM Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive DisorderJanuary 21, 2016 7:00 AM